Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
en_news
Chemotherapy resistance is often driven by cancer cells entering into a slow-cycling or dormant state to evade therapy-induced cell death….
Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients Inaugural Scientific Summit Prioritized Advancing…
Now published in EJC – European Journal of Cancer (1), results of a retrospective study led by investigators of VHIO’s…
Results of exploratory analysis of overall survival data from the pivotal phase III IMpower010 study were presented on the ground…
Researchers at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus, have found that breast milk…
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that represents about 15% of breast cancer cases. Classified as…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
An International Workgroup of Cancer Genetics Experts Convened by the American College of Medical Genetics and Genomics Develops Guidance on…
Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…
